PULMICORT FLEXHALER Rx
Generic Name and Formulations:
Budesonide (micronized) 90mcg/inh, 180mcg/inh; dry pwd for inhalation.
Indications for PULMICORT FLEXHALER:
Maintenance treatment of asthma as prophylactic therapy. Asthma requiring systemic corticosteroid therapy, to reduce need for systemic corticosteroids.
≥18yrs: Initially 360mcg twice daily; may consider starting at 180mcg twice daily, if appropriate. Max 720mcg twice daily. Rinse mouth after use.
<6yrs: not recommended. ≥6yrs: Initially 180mcg twice daily; may consider starting at 360mcg twice daily, if appropriate. Max 360mcg twice daily. Rinse mouth after use.
Not for primary treatment of acute attack.
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider antiinfective prophylactic therapy. Adrenal insufficiency may occur when transferring patients from systemic corticosteroids to inhaled corticosteroids: see literature. Monitor for growth suppression in children. Post-op or during stress: monitor adrenal response. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually). Transferring from oral corticosteroids: see literature. Pregnancy (Cat.B). Nursing mothers: not recommended.
Caution with CYP3A4 inhibitors (eg, ketoconazole).
Pulmicort Flexhaler: nasal congestion, allergic rhinitis, viral upper respiratory tract infection, oral candidiasis, viral gastroenteritis, nausea, bronchospasm (rare). Pulmicort Respules: Respiratory or other infection, GI upset, moniliasis, fatigue, cough, dysphonia, rash, epistaxis, hypersensitivity reactions (discontinue if occurs).
Respules (YES); Flexhaler (NO)
Flexhaler (90mcg/dose)—1 (60 inh); Flexhaler (180mcg/dose)—1 (120 inh); Respules—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities